The psychological assessment of subjects participating in clinical trials has become an important part of the section's research interest. Several studies were conducted: a comparison of drug abusers seeking treatment and not seeking treatment; an evaluation of personality disorders in cocaine dependent individuals seeking research treatment; and a survey of motivation for treatment. An important issue facing researchers and treatment providers is the reporting and representation of women and minorities in cocaine abuse pharmacotherapy clinical trials. Sociodemographic representation in 61 reports of outpatient pharmacotherapy for cocaine abuse, published in refereed, English language journals, between 1983 and 1993 was compared to the epidemiology of frequent cocaine use in the 1990 NIDA National Household Survey of Drug Abuse (NIDA-HS). The findings showed that important sociodemographic data is often not reported in papers, and raise issues of quality of research reports, generalizability of results, social equity, and accessibility for certain groups in cocaine abuse pharmacotherapy research. In procedural studies to identify improved outcome variable in clinical trials, the usefulness of quantitative urinalysis for cocaine metabolite and creatinine correction techniques and the relationship between these data and self-reported drug use were assessed with data collected in a clinical trial (N = 37) of a contingency management behavioral treatment intervention. Rules were developed to differentiate between occasions of new use and carry-over in positive qualitative urine tests. Preliminary analyses suggest: qualitative and quantitative urine testing show greater rates of drug use than that shown by self report; quantitative testing provides a means of differentiating incidences of new drug use from residual carry-over; the identification of new use with quantitative testing may help to reconcile differences between rates of drug use indicated by qualitative urine screens and self-report. Sweat patches have been proven effective in measuring cocaine and opiate use in controlled clinical laboratory settings but have not previously been tested under more realistic settings such as our treatment clinic. Collection of sweat as a method of monitoring drug use may be more accurate and reliable over a longer period of time than the urine testing method currently used. The purpose to evaluate the effectiveness of collecting sweat as an alternative method of monitoring drug use. Results will be compared to drug use as monitored by urine samples collected three times a week.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Intramural Research (Z01)
Project #
1Z01DA000234-01
Application #
3752866
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
National Institute on Drug Abuse
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Kowalczyk, William J (2017) The utility of geographically-explicit ecological momentary assessment: from description to intervention. Soc Psychiatry Psychiatr Epidemiol 52:131-133
Ghitza, Udi E; Epstein, David H; Preston, Kenzie L (2008) Self-report of illicit benzodiazepine use on the Addiction Severity Index predicts treatment outcome. Drug Alcohol Depend 97:150-7
Ghitza, Udi E; Epstein, David H; Preston, Kenzie L (2007) Psychosocial functioning and cocaine use during treatment: strength of relationship depends on type of urine-testing method. Drug Alcohol Depend 91:169-77
Heinz, Adrienne; Epstein, David H; Preston, Kenzie L (2007) Spiritual/Religious experiences and in-treatment outcome in an inner-city program for heroin and cocaine dependence. J Psychoactive Drugs 39:41-9
Ghitza, Udi E; Epstein, David H; Preston, Kenzie L (2007) Nonreporting of cannabis use: Predictors and relationship to treatment outcome in methadone maintained patients. Addict Behav 32:938-49
Carroll, C Patrick; Walsh, Sharon L; Bigelow, George E et al. (2006) Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans. Exp Clin Psychopharmacol 14:109-20
Epstein, David H; Preston, Kenzie L; Jasinski, Donald R (2006) Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biol Psychol 73:90-9
Heinz, Adrienne J; Epstein, David H; Schroeder, Jennifer R et al. (2006) Heroin and cocaine craving and use during treatment: measurement validation and potential relationships. J Subst Abuse Treat 31:355-64
Schroeder, Jennifer R; Epstein, David H; Umbricht, Annie et al. (2006) Changes in HIV risk behaviors among patients receiving combined pharmacological and behavioral interventions for heroin and cocaine dependence. Addict Behav 31:868-79
Schroeder, Jennifer R; Schmittner, John P; Epstein, David H et al. (2005) Adverse events among patients in a behavioral treatment trial for heroin and cocaine dependence: effects of age, race, and gender. Drug Alcohol Depend 80:45-51

Showing the most recent 10 out of 32 publications